ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$14.62 USD
-0.19 (-1.28%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $14.62 0.00 (0.00%) 4:32 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
ACAD 14.62 -0.19(-1.28%)
Will ACAD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACAD
Should You Buy, Sell or Hold McKesson Before Q2 Earnings?
Cencora to Report Q4 Earnings: What's in Store for the Stock?
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
Revvity to Report Q3 Earnings: What's in Store for the Stock?
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for ACAD
Health Canada grants approval of Acadia's Rett syndrome treatment
Morgan Stanley Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD)
Nike upgraded, PayPal downgraded: Wall Street's top analyst calls
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
Acadia Pharmaceuticals reinstated with a Market Perform at Raymond James